Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background: Limited evidence is available regarding the anaphylaxis risk following the administration of COVID-19 therapeutics. Methods: With the approval of NHS England, we conducted a descriptive analysis of anaphylaxis events following COVID-19 treatment for non-hospitalised patients using routine clinical data from 24 million people in England in the OpenSAFELY-TPP database. Results: We found that the risk of anaphylaxis during the 29 days follow-up was 0.04% for sotrovimab users, 0.03% for Paxlovid users, <0.05% for molnupiravir users, and 0.02% for untreated high-risk patients. Conclusions: Our results suggest that anaphylaxis risks were similar between sotrovimab and Paxlovid users, which were not appreciably different from untreated patients.

Original publication




Journal article


Wellcome Open Research


F1000 Research Ltd

Publication Date





387 - 387